Market Overview

UPDATE: Bank of America Downgrades Hospira to Neutral on Cash Flow Guidance

Share:
Related HSP
Earnings Scheduled For July 29, 2015
5 Best-Performing S&P 500 Stocks Of 2015
The Medicines Co. Down on Wider-than-Expected Loss in Q2 - Analyst Blog (Zacks)

Bank of America downgraded Hospira (NYSE: HSP) from Buy to Neutral and reduced the price target from $44.00 to $38.00.

Bank of America commented, "HSP announced ‘13 guidance on its 4Q earnings call, and while management's revenue and EPS outlook is roughly consistent with ours, we were disappointed by cash flow guidance. In addition, HSP announced that (1) it is in the midst of deciding on its strategy for remediating its pumps business, which creates some new uncertainty (could have implications for costs and potentially for revenue), and (2) the long-awaited FDA re-inspection of the Rocky Mount facility has just begun, and management plans to summarize the results when complete (guidance assumes a “successful” outcome), potentially within a month or two."

Hospira closed at $34.03 on Tuesday.

Latest Ratings for HSP

DateFirmActionFromTo
Feb 2015Goldman SachsUpgradesSellNeutral
Jan 2015Deutsche BankMaintainsBuy
Dec 2014BarclaysMaintainsEqual-weight

View More Analyst Ratings for HSP
View the Latest Analyst Ratings

Posted-In: Bank of AmericaAnalyst Color Downgrades Analyst Ratings

 

Related Articles (HSP)

Get Benzinga's Newsletters